3.22.4 html 43 123 1 false 12 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://peakpharma.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://peakpharma.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://peakpharma.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://peakpharma.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://peakpharma.com/role/ConsolidatedStatementsOfOperationsParenthetical CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (EQUITY) Sheet http://peakpharma.com/role/ConsolidatedStatementOfStockholdersDeficitEquity CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (EQUITY) Statements 6 false false R7.htm 00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://peakpharma.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 00000008 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://peakpharma.com/role/NatureOfOperationsBasisOfPresentationAndSummaryOfSignificantAccountingPolicies NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - GOING CONCERN AND MANAGEMENT???S LIQUIDITY PLANS Sheet http://peakpharma.com/role/GoingConcernAndManagementsLiquidityPlans GOING CONCERN AND MANAGEMENT???S LIQUIDITY PLANS Notes 9 false false R10.htm 00000010 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://peakpharma.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 10 false false R11.htm 00000011 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTES PAYABLE Notes http://peakpharma.com/role/ConvertibleNotesPayableAndNotesPayable CONVERTIBLE NOTES PAYABLE AND NOTES PAYABLE Notes 11 false false R12.htm 00000012 - Disclosure - STOCK OPTIONS Sheet http://peakpharma.com/role/StockOptions STOCK OPTIONS Notes 12 false false R13.htm 00000013 - Disclosure - INCOME TAXES Sheet http://peakpharma.com/role/IncomeTaxes INCOME TAXES Notes 13 false false R14.htm 00000014 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://peakpharma.com/role/NatureOfOperationsBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 14 false false R15.htm 00000015 - Disclosure - STOCK OPTIONS (Tables) Sheet http://peakpharma.com/role/StockOptionsTables STOCK OPTIONS (Tables) Tables http://peakpharma.com/role/StockOptions 15 false false R16.htm 00000016 - Disclosure - INCOME TAXES (Tables) Sheet http://peakpharma.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://peakpharma.com/role/IncomeTaxes 16 false false R17.htm 00000017 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://peakpharma.com/role/NatureOfOperationsBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://peakpharma.com/role/NatureOfOperationsBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies 17 false false R18.htm 00000018 - Disclosure - GOING CONCERN AND MANAGEMENT???S LIQUIDITY PLANS (Details Narrative) Sheet http://peakpharma.com/role/GoingConcernAndManagementsLiquidityPlansDetailsNarrative GOING CONCERN AND MANAGEMENT???S LIQUIDITY PLANS (Details Narrative) Details http://peakpharma.com/role/GoingConcernAndManagementsLiquidityPlans 18 false false R19.htm 00000019 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://peakpharma.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://peakpharma.com/role/RelatedPartyTransactions 19 false false R20.htm 00000020 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTES PAYABLE (Details Narrative) Notes http://peakpharma.com/role/ConvertibleNotesPayableAndNotesPayableDetailsNarrative CONVERTIBLE NOTES PAYABLE AND NOTES PAYABLE (Details Narrative) Details http://peakpharma.com/role/ConvertibleNotesPayableAndNotesPayable 20 false false R21.htm 00000021 - Disclosure - OPTIONS (Details) Sheet http://peakpharma.com/role/OptionsDetails OPTIONS (Details) Details 21 false false R22.htm 00000022 - Disclosure - OPTIONS (Details 2) Sheet http://peakpharma.com/role/OptionsDetails2 OPTIONS (Details 2) Details 22 false false R23.htm 00000023 - Disclosure - INCOME TAXES (Details) Sheet http://peakpharma.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://peakpharma.com/role/IncomeTaxesTables 23 false false R24.htm 00000024 - Disclosure - INCOME TAXES (Details 2) Sheet http://peakpharma.com/role/IncomeTaxesDetails2 INCOME TAXES (Details 2) Details http://peakpharma.com/role/IncomeTaxesTables 24 false false R25.htm 00000025 - Disclosure - INCOME TAXES (Details 3) Sheet http://peakpharma.com/role/IncomeTaxesDetails3 INCOME TAXES (Details 3) Details http://peakpharma.com/role/IncomeTaxesTables 25 false false R26.htm 00000026 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://peakpharma.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://peakpharma.com/role/IncomeTaxesTables 26 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept WeightedAverageNumberOfShareOutstandingBasicAndDiluted in us-gaap/2021 used in 2 facts was deprecated in us-gaap/2022 as of 2022 and should not be used. pkph093021-10k.htm 4083, 4084 [dq-0542-Deprecated-Concept] Concept EarningsPerShareBasicAndDiluted in us-gaap/2021 used in 2 facts was deprecated in us-gaap/2022 as of 2022 and should not be used. pkph093021-10k.htm 4091, 4092 [dq-0542-Deprecated-Concept] Concept CashPeriodIncreaseDecrease in us-gaap/2021 used in 2 facts was deprecated in us-gaap/2022 as of 2022 and should not be used. pkph093021-10k.htm 4295, 4296 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 9 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 - pkph093021-10k.htm 25, 44, 45, 46, 47, 48, 49, 50, 51 [dqc-0048-Required-Calculation-Parent-Element-In-The-Cash-Flow-Statement] The filing should include in the cash flow statement calculation linkbase(s) http://peakpharma.com/role/IncomeTaxesDetailsNarrative - 00000026 - Disclosure - INCOME TAXES (Details Narrative) one of the following elements as the root(first element) of the calculation tree to represent the aggregate change in cash for the period: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect, CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect, NetCashProvidedByUsedInContinuingOperations (As long as the element NetCashProvidedByUsedInDiscontinuedOperations is also included the reconciliation between opening and closing cash). The calculation linkbase in the filing has the following root elements defined: CashPeriodIncreaseDecrease. Rule Element Id: 7482. pkph093021-10k.htm pkph093021-10k.htm pkph-20210930.xsd pkph-20210930_cal.xml pkph-20210930_def.xml pkph-20210930_lab.xml pkph-20210930_pre.xml pkph093021-ex10_10.htm pkph093021-ex10_11.htm pkph093021-ex10_12.htm pkph093021-ex10_13.htm pkph093021-ex10_14.htm pkph093021-ex10_15.htm pkph093021-ex10_16.htm pkph093021-ex10_17.htm pkph093021-ex10_18.htm pkph093021-ex10_19.htm pkph093021-ex10_20.htm pkph093021-ex31_1.htm pkph093021-ex31_2.htm pkph093021-ex32_1.htm pkph093021-ex32_2.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true